SMAD2 and breast carcinoma: A limited number of studies investigated the prognostic relevance of phosphorylated SMAD2 (pSMAD2) as an indicator of active TGF-β signaling in diagnostic breast cancer tissues, with both suggesting an adverse prognosis and an increased risk of disease recurrence [36, 38].